Bone loss occurs in Inflammatory Rheumatic Musculoskeletal Diseases (iRMD) patients treated with low dose glucocorticoids, but is prevented by anti-osteoporosis medications.
Giovanni AdamiAngelo FassioMaurizio RossiniCamilla BeniniFrancesca PistilloOmbretta ViapianaDavide BertelleDavide GattiPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
GC doses as low as 2.5 mg/day were associated with BMD loss in iRMD but this effect was preventable. BMD loss in patients taking ≥5 mg/day was not totally prevented by anti-osteoporotic medications currently used in clinical practice, resulting in higher risk of fracture. This article is protected by copyright. All rights reserved.
Keyphrases
- low dose
- bone loss
- clinical practice
- end stage renal disease
- newly diagnosed
- bone mineral density
- ejection fraction
- chronic kidney disease
- postmenopausal women
- prognostic factors
- oxidative stress
- peritoneal dialysis
- rheumatoid arthritis
- emergency department
- patient reported
- hip fracture
- body composition
- gas chromatography
- drug induced